Dr. Reddy's Reports Near Double-Digit Revenue Growth, Steady Profitability in Q2 FY26, Releases Investor Presentation
Dr. Reddy's reported Q2 FY26 revenues of ₹ 8,805 crore and PAT of ₹ 1,437 crore, with near double-digit growth. Strategic acquisitions and new product launches drove performance, alongside progress in ESG and pipeline development.
The announcement details strong financial results and significant strategic advancements, which are positive for the company. However, the regulatory observations from the USFDA at multiple facilities and softness in North America generics moderate the overall immediate positive impact, making it a medium impact rather than high.
The company reported near double-digit revenue growth and a significant 14% YoY increase in PAT. Strategic acquisitions, multiple new product launches in India and other markets, and progress in pipeline development (Semaglutide, denosumab biosimilar) indicate strong operational performance and future growth prospects. ESG ratings also improved.
Dr. Reddy's Laboratories Limited released its Investor Presentation for the unaudited financial results for the quarter and half-year ended September 30, 2025 (Q2 FY26). Key financial highlights for Q2 FY26 (consolidated under IFRS) include: * Revenues: ₹ 8,805 crore, a 9.8% YoY and 3% QoQ growth. * EBITDA: ₹ 2,351 crore (26.7% of revenues), a 3% YoY and 3% QoQ growth. * PBT: ₹ 1,835 crore (20.8% of revenues), a 4% YoY and 4% QoQ growth. * PAT (attributable to equity shareholders): ₹ 1,437 crore (16.3% of revenues), a 14% YoY and 1% QoQ growth. * Annualised RoCE: approximately 22%. * Net Cash surplus: ₹ 2,751 crore as of September 30, 2025.
Business highlights for Q2 FY26 include: * Acquired Stugeron® and related brands for 18 markets in APAC and EMEA for US$50 million (₹ 417.5 crore). * Launched two novel Gastro-Intestinal drugs in India: Tegoprazan as 'PCAB®' and Linaclotide as 'Colozo®'. * Partnered with Unitaid, Clinton Health Access Initiative, and Wits RHI to make HIV prevention tool, Lenacapavir, accessible in LMICs. * Approval for Semaglutide injection in India recommended by SEC under CDSCO. * Positive opinion from EMA’s CHMP for its denosumab biosimilar candidate. * IND application for COYA 302 accepted by USFDA. * NRT integration is progressing well, with 2/3rd business value integrated. * North America revenues: ₹ 3,241 crore, up 13% YoY but down 5% QoQ, impacted by price erosion and lower Lenalidomide sales. Launched Sacubitril Valsartan Tablets (generic Entresto®) and an authorized generic of Fluorouracil Cream. * India revenues: ₹ 1,578 crore, up 13% YoY and 7% QoQ, driven by new brand launches, improved pricing, and higher volumes. * Emerging Markets revenues: ₹ 1,655 crore, up 14% YoY and 18% QoQ, driven by new product launches and favorable forex. * Europe revenues: ₹ 1,376 crore, up 138% YoY and 8% QoQ, underpinned by the acquired NRT business. * PSAI revenues: ₹ 945 crore, up 12% YoY but down 16% QoQ.
Other highlights: * MSCI ESG Rating of ‘A’ for the 2nd consecutive year, Morningstar Sustainalytics' ESG Risk Rating improved to 18.4 (low risk). * FTO-11 (Srikakulam) received ‘LEED Platinum certification’. * Regulatory updates: FTO-11 and CTO-5 Middleburgh classified as ‘VAI’ post GMP inspections. USFDA conducted PAI at biologics facility (Bachupally) and GMP inspection at Mirfield (UK) API facility, issuing Form 483 with 5 and 7 observations respectively.
The company's strategic focus includes strengthening core businesses, advancing key pipeline products, strengthening capabilities, driving efficiencies, focusing on quality, compliance, and sustainability, and augmenting organic growth with M&A and in-licensing.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.